Microglial priming in neurodegenerative disease

Nature Reviews Neurology

Volumn 10, Issue 4, 2014, Pages 217-224

  Perry, V Hugh ^a   Holmes, Clive ^b  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E4; CLUSTERIN; COMPLEMENT COMPONENT C3B; COMPLEMENT COMPONENT C3B RECEPTOR; COMPLEMENT COMPONENT C4B; CYTOKINE; FC RECEPTOR; GAMMA INTERFERON; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 1; INTERLEUKIN 6; KILLER CELL ACTIVATING RECEPTOR ASSOCIATED PROTEIN; MEMBRANE ANTIGEN; MONOCYTE CHEMOTACTIC PROTEIN 1; NITRIC OXIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; ROSIGLITAZONE; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR INHIBITOR;

ALZHEIMER DISEASE; CELL ACTIVATION; CENTRAL NERVOUS SYSTEM DISEASE; DEGENERATIVE DISEASE; DRUG TARGETING; ENCEPHALITIS; GENETIC ASSOCIATION; GENETIC RISK; HUMAN; LIFESTYLE MODIFICATION; MACROPHAGE; MICROENVIRONMENT; MICROGLIA; MISSENSE MUTATION; MOLECULAR MECHANICS; NEUROPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

ALZHEIMER DISEASE; ANIMALS; ANTI-INFLAMMATORY AGENTS; BRAIN; CENTRAL NERVOUS SYSTEM DISEASES; HUMANS; INFLAMMATION; MACROPHAGE ACTIVATION; MICROGLIA; NEURODEGENERATIVE DISEASES;

EID: 84897976299     PISSN: 17594758     EISSN: 17594766     Source Type: Journal    
DOI: 10.1038/nrneurol.2014.38     Document Type: Review

References (119)

1. de Haas, A. H., Boddeke, H. W. & Biber, K. Region-specific expression of immunoregulatory proteins on microglia in the healthy CNS. Glia 56, 888-894 (2008
2. Ransohoff, R. M. & Perry, V. H. Microglial physiology: Unique stimuli, specialized responses. Annu. Rev. Immunol. 27, 119-145 (2009
3. Gautier, E. L. et al. Gene-expression profiles and transcriptional regulatory pathways that underlie the identity and diversity of mouse tissue macrophages. Nat. Immunol. 13, 1118-1128 (2012
4. Nimmerjahn, A., Kirchhoff, F. & Helmchen, F. Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science 308, 1314-1318 (2005
5. Wake, H., Moorhouse, A. J., Jinno, S., Kohsaka, S. & Nabekura, J. Resting microglia directly monitor the functional state of synapses in vivo and determine the fate of ischemic terminals. J. Neurosci. 29, 3974-3980 (2009
6. Tremblay, M. E., Lowery, R. L. & Majewska, A. K. Microglial interactions with synapses are modulated by visual experience. PLoS Biol. 8, e1000527 (2010
7. Sogn, C. J., Puchades, M. & Gundersen, V. Rare contacts between synapses and microglial processes containing high levels of Iba1 and actin-A postembedding immunogold study in the healthy rat brain. Eur. J. Neurosci. 38, 2030-2040 (2013
8. Dantzer, R., O'Connor, J. C., Freund, G. G., Johnson, R. W. & Kelley, K. W. From inflammation to sickness and depression: When the immune system subjugates the brain. Nat. Rev. Neurosci. 9, 46-56 (2008
9. Andersson, U. & Tracey, K. J. Reflex principles of immunological homeostasis. Annu. Rev. Immunol. 30, 313-335 (2012
10. Perry, V. H. The influence of systemic inflammation on inflammation in the brain: Implications for chronic neurodegenerative disease. Brain Behav. Immun. 18, 407-413 (2004
11. Perry, V. H., Cunningham, C. & Holmes, C. Systemic infections and inflammation affect chronic neurodegeneration. Nat. Rev. Immunol. 7, 161-167 (2007
12. Mosser, D. M. & Edwards, J. P. Exploring the full spectrum of macrophage activation. Nat. Rev. Immunol. 8, 958-969 (2008
13. Colton, C. A., Mott, R. T., Sharpe, H., Xu, Q. & Van Nostrand, W. E. Expression profiles for macrophage alternative activation genes in AD and in mouse models of AD. J. Neuroinflammation 3, 27 (2006
14. Perry, V. H. Contribution of systemic inflammation to chronic neurodegeneration. Acta Neuropathol. 120, 277-286 (2010
15. Scheffel, J. et al. Toll-like receptor activation reveals developmental reorganization and unmasks responder subsets of microglia. Glia 60, 1930-1943 (2012
16. Ravasi, T. et al. Generation of diversity in the innate immune system: Macrophage heterogeneity arises from gene-Autonomous transcriptional probability of individual inducible genes. J. Immunol. 168, 44-50 (2002
17. Combrinck, M. I., Perry, V. H. & Cunningham, C. Peripheral infection evokes exaggerated sickness behaviour in pre-clinical murine prion Disease. Neuroscience 112, 7-11 (2002
18. Cunningham, C., Wilcockson, D. C., Campion, S., Lunnon, K. & Perry, V. H. Central and systemic endotoxin challenges exacerbate the local inflammatory response and increase neuronal death during chronic neurodegeneration. J. Neurosci. 25, 9275-9284 (2005
19. Cunningham, C. et al. Systemic inflammation induces acute behavioral and cognitive changes and accelerates neurodegenerative disease. Biol. Psychiatry 65, 304-312 (2009
20. Field, R., Campion, S., Warren, C., Murray, C. & Cunningham, C. Systemic challenge with the TLR3 agonist poly I:C induces amplified IFNa/β and IL 1β responses in the diseased brain and exacerbates chronic neurodegeneration. Brain Behav. Immun. 24, 996-1007 (2010
21. Cunningham, C. Microglia and neurodegeneration: The role of systemic inflammation. Glia 61, 71-90 (2013
22. Püntener, U., Booth, S. G., Perry, V. H. & Teeling, J. L. Long-Term impact of systemic bacterial infection on the cerebral vasculature and microglia. J. Neuroinflammation 9, 146 (2012
23. Ohmoto, Y. et al. Variation in the immune response to adenoviral vectors in the brain: Influence of mouse strain, environmental conditions and priming. Gene Ther. 6, 471-481 (1999
24. McColl, B. W., Rothwell, N. J. & Allan, S. M. Systemic inflammatory stimulus potentiates the acute phase and CXC chemokine responses to experimental stroke and exacerbates brain Damage via interleukin 1 and neutrophil-dependent mechanisms. J. Neurosci. 27, 4403-4412 (2007
25. Maitra, U. et al. Molecular mechanisms responsible for the selective and low-grade induction of proinflammatory mediators in murine macrophages by lipopolysaccharide. J. Immunol. 189, 1014-1023 (2012
26. Khalif, I. L., Quigley, E. M., Konovitch, E. A. & Maximova, I. D. Alterations in the colonic flora and intestinal permeability and evidence of immune activation in chronic constipation. Dig. Liver Dis. 37, 838-849 (2005
27. Khoo, T. K. et al. The spectrum of nonmotor symptoms in early Parkinson Disease. Neurology 80, 276-281 (2013
28. Correale, J. & Farez, M. Association between parasite infection and immune responses in multiple sclerosis. Ann. Neurol. 61, 97-108 (2007
29. Buljevac, D. et al. Prospective study on the relationship between infections and multiple sclerosis exacerbations. Brain 125, 952-960 (2002
30. Schroder, K., Sweet, M. J. & Hume, D. A. Signal integration between IFN? and TLR signalling pathways in macrophages. Immunobiology 211, 511-524 (2006
31. Chapoval, A. I., Kamdar, S. J., Kremlev, S. G. & Evans, R. CSF 1 (M-CSF) differentially sensitizes mononuclear phagocyte subpopulations to endotoxin in vivo: A potential pathway that regulates the severity of gram-negative infections. J. Leukoc. Biol. 63, 245-252 (1998
32. Rankine, E. L., Hughes, P. M., Botham, M. S., Perry, V. H. & Felton, L. M. Brain cytokine synthesis induced by an intraparenchymal injection of LPS is reduced in MCP 1 deficient mice prior to leucocyte recruitment. Eur. J. Neurosci. 24, 77-86 (2006
33. Bhattacharyya, S. et al. Chemokine-induced leishmanicidal activity in murine macrophages via the generation of nitric oxide. J. Infect. Dis. 185, 1704-1708 (2002
34. Greter, M. et al. Stroma-derived interleukin 34 controls the development and maintenance of Langerhans cells and the maintenance of microglia. Immunity. 37, 1050-1060 (2012
35. Wang, Y. et al. IL 34 is a tissue-restricted ligand of CSF1R required for the development of Langerhans cells and microglia. Nat. Immunol. 13, 753-760 (2012
36. Gómez-Nicola, D., Fransen, N. L., Suzzi, S. & Perry, V. H. Regulation of microglial proliferation During chronic neurodegeneration. J. Neurosci. 33, 2481-2493 (2013
37. Hinojosa, A. E., Garcia-Bueno, B., Leza, J. C. & Madrigal, J. L. CCL2/MCP 1 modulation of microglial activation and proliferation. J. Neuroinflammation 5, 77 (2011
38. Krstic, D. et al. Systemic immune challenges trigger and drive Alzheimer-like neuropathology in mice. J. Neuroinflammation 9, 151 (2012
39. Lunnon, K. et al. Systemic inflammation modulates Fc receptor expression on microglia during chronic neurodegeneration. J. Immunol. 186, 7215-7224 (2011
40. Boche, D., Denham, N., Holmes, C. & Nicoll, J. A. Neuropathology after active Aβ42 immunotherapy: Implications for Alzheimer's disease pathogenesis. Acta Neuropathol. 120, 369-384 (2010
41. Kitazawa, M., Oddo, S., Yamasaki, T. R., Green, K. N. & LaFerla, F. M. Lipopolysaccharide-induced inflammation exacerbates tau pathology by a cyclin-dependent kinase 5 mediated pathway in a transgenic model of Alzheimer's disease. J. Neurosci. 25, 8843-8853 (2005
42. Pott Godoy, M. C., Ferrari, C. C. & Pitossi, F. J. Nigral neurodegeneration triggered by striatal AdIL 1 administration can be exacerbated by systemic IL 1 expression. J. Neuroimmunol. 222, 29-39 (2010
43. Moreno, B. et al. Systemic inflammation induces axon injury during brain inflammation. Ann. Neurol. 70, 932-942 (2011
44. Warren, H. S. et al. Resilience to bacterial infection: Difference between species could be due to proteins in serum. J. Infect. Dis. 201, 223-232 (2010
45. Taveira da Silva, A. M. et al. Brief report: Shock and multiple-organ Dysfunction after self-Administration of Salmonella endotoxin. N. Engl. J. Med. 328, 1457-1460 (1993
46. Sauter, C. & Wolfensberger, C. Interferon in human serum after injection of endotoxin. Lancet 2, 852-853 (1980
47. Brydon, L., Harrison, N. A., Walker, C., Steptoe, A. & Critchley, H. D. Peripheral inflammation is associated with altered substantia nigra activity and psychomotor slowing in humans. Biol. Psychiatry 63, 1022-1029 (2008
48. Harrison, N. A. et al. Inflammation causes mood changes through alterations in subgenual cingulate activity and mesolimbic connectivity. Biol. Psychiatry 66, 407-414 (2009
49. Hannestad, J. et al. Endotoxin-induced systemic inflammation activates microglia: [11C] PBR28 positron emission tomography in nonhuman primates. Neuroimage 63, 232-239 (2012
50. Drake, C. et al. Brain inflammation is induced by co-morbidities and risk factors for stroke. Brain Behav. Immun. 25, 1113-1122 (2011
51. Thaler, J. P. et al. Obesity is associated with hypothalamic injury in rodents and humans. J. Clin. Invest. 122, 153-162 (2012
52. Li, J., Tang, Y. & Cai, D. IKKβ/NF-?B disrupts adult hypothalamic neural stem cells to mediate a neurodegenerative mechanism of dietary obesity and pre-diabetes. Nat. Cell Biol. 14, 999-1012 (2012
53. Zhang, G. et al. Hypothalamic programming of systemic ageing involving IKK-β, NF ?B and GnRH. Nature 497, 211-216 (2013
54. Casserly, I. & Topol, E. Convergence of atherosclerosis and Alzheimer's disease: Inflammation, cholesterol, and misfolded proteins. Lancet 363, 1139-1146 (2004
55. Balakrishnan, K. et al. Plasma Aβ42 correlates positively with increased body fat in healthy individuals. J. Alzheimers Dis. 8, 269-282 (2005
56. Donath, M. Y. & Shoelson, S. E. Type 2 diabetes as an inflammatory disease. Nat. Rev. Immunol. 11, 98-107 (2011
57. Paloneva, J. et al. Mutations in two genes encoding different subunits of a receptor signaling complex result in an identical disease phenotype. Am. J. Hum. Genet. 71, 656-662 (2002
58. Kaneko, M., Sano, K., Nakayama, J. & Amano, N. Nasu-Hakola disease: The first case reported by Nasu and review. Neuropathology 30, 463-470 (2010
59. Chitu, V. & Stanley, E. R. Colony-stimulating factor 1 in immunity and inflammation. Curr. Opin. Immunol. 18, 39-48 (2006
60. Nicholson, A. M. et al. CSF1R mutations link POLD and HDLS as a single disease entity. Neurology 12, 1033-1040 (2013
61. Franceschi, C. et al. Inflammaging and anti-inflammaging: A systemic perspective on aging and longevity emerged from studies in humans. Mech. Ageing Dev. 128, 92-105 (2007
62. Clark, I. A. & Atwood, C. S. Is TNF a link between aging-related reproductive endocrine dyscrasia and Alzheimer's disease?. J. Alzheimers Dis. 27, 691-699 (2011
63. Butchart, J., Birch, B., Bassily, R., Wolfe, L. & Holmes, C. Male sex hormones and systemic inflammation in Alzheimer disease. Alzheimer Dis. Assoc. Disord. 27, 153-156 (2013
64. Cribbs, D. H. et al. Extensive innate immune gene activation accompanies brain aging, increasing vulnerability to cognitive decline and neurodegeneration: A microarray study. J. Neuroinflammation 9, 179 (2012
65. Lemstra, A. W. et al. Microglia activation in sepsis: A case-control study. J. Neuroinflammation 15, 4 (2007
66. Sudduth, T. L., Schmitt, F. A., Nelson, P. T. & Wilcock, D. M. Neuroinflammatory phenotype in early Alzheimer's disease. Neurobiol. Aging 34, 1051-1059 (2013
67. Swardfager, W. et al. A meta-Analysis of cytokines in Alzheimer's disease. Biol. Psychiatry 68, 930-941 (2010
68. Boyle, P. A. et al. Physical frailty is associated with incident mild cognitive impairment in community-based older persons. J. Am. Geriatr. Soc. 58, 248-255 (2010
69. Anand, S., Johansen, K. L. & Kurella Tamura, M. Aging and chronic kidney disease: The impact on physical function and cognition. J. Gerontol. A Biol. Sci. Med. Sci. 69, 315-322 (2014
70. Marioni, R. E. et al. Association between raised inflammatory markers and cognitive decline in elderly people with type 2 diabetes: The Edinburgh Type 2 Diabetes Study. Diabetes 59, 710-713 (2010
71. Barnett, K. et al. Epidemiology of multimorbidity and implications for health care, research, and medical education: A cross-sectional study. Lancet 380, 37-43 (2012
72. Holmes, C. et al. Systemic inflammation and disease progression in Alzheimer disease. Neurology 73, 768-774 (2009
73. Holmes, C., Cunningham, C., Zotova, E., Culliford, D. & Perry, V. H. Proinflammatory cytokines, sickness behavior, and Alzheimer disease. Neurology 77, 212-218 (2011
74. Barger, S. W. & Harmon, A. D. Microglial activation by Alzheimer amyloid precursor protein and modulation by apolipoprotein E. Nature 388, 878-881 (1997
75. Itzhaki, R. F. & Wozniak, M. A. Herpes simplex virus type 1, apolipoprotein E, and cholesterol: A dangerous liaison in Alzheimer's disease and other disorders. Prog. Lipid Res. 45, 73-90 (2006
76. Gerard, H. C. et al. The load of Chlamydia pneumoniae in the Alzheimer's brain varies with APOE genotype. Microb. Pathog. 39, 9-26 (2005
77. Moretti, E. W. et al. APOE polymorphism is associated with risk of severe sepsis in surgical patients. Crit. Care Med. 33, 2521-2526 (2005
78. Harold, D. et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat. Genet. 41, 1088-1093 (2009
79. Lambert, J. C. et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat. Genet. 41, 1094-1109 (2009
80. Nuutinen, T., Suuronen, T., Kauppinen, A. & Salminen, A. Clusterin: A forgotten player in Alzheimer's disease. Brain Res. Rev. 61, 89-104 (2009
81. Jones, L. et al. Genetic evidence implicates the immune system and cholesterol metabolism in the aetiology of Alzheimer's disease. PLoS ONE 15, e13950 (2010
82. Hollingworth, P. et al. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat. Genet. 43, 429-435 (2011
83. Naj, A. C. et al. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat. Genet. 43, 436-441 (2011
84. Bradshaw, E. M. et al. CD33 Alzheimer's disease locus: Altered monocyte function and amyloid biology. Nat. Neurosci. 16, 848-850 (2013
85. Ishibashi, K., Suzuki, M., Sasaki, S. & Imai, M. Identification of a new multigene four-Transmembrane family (MS4A) related to CD20, HTm4 and β subunit of the high-Affinity IgE receptor. Gene 264, 87-93 (2001
86. Tanaka, N., Abe-Dohmae, S., Iwamoto, N. & Yokoyama, S. Roles of ATP-binding cassette transporter A7 in cholesterol homeostasis and host defense system. J. Atheroscler. Thromb. 18, 274-281 (2011
87. Dustin, M. L. et al. A novel adaptor protein orchestrates receptor patterning and cytoskeletal polarity in T cell contacts. Cell 94, 667-677 (1998
88. Aasheim, H. C., Delabie, J. & Finne, E. F. Ephrin A1 binding to CD4+ T lymphocytes stimulates migration and induces tyrosine phosphorylation of PYK2. Blood 105, 2869-2876 (2005
89. Guerreiro, R. et al. TREM2 variants in Alzheimer's disease. N. Engl. J. Med. 368, 117-127 (2013
90. Jonsson, T. et al. Variant of TREM2 associated with the risk of Alzheimer's disease. N. Engl. J. Med. 368, 107-116 (2013
91. Neumann, H. & Takahashi, K. Essential role of the microglial triggering receptor expressed on myeloid cells 2 (TREM2) for central nervous tissue immune homeostasis. J. Neuroimmunol. 184, 92-99 (2007
92. Rogers, J. et al. Clinical trial of indomethacin in Alzheimer's disease. Neurology 43, 1609-1611 (1993
93. de Jong, D. et al. No effect of one-year treatment with indomethacin on Alzheimer's disease progression: A randomized controlled trial. PLoS ONE 23, e1475 (2008
94. Aisen, P. S. et al. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: A randomized controlled trial. JAMA 289, 2819-2826 (2003
95. Gold, M. et al. Rosiglitazone monotherapy in mild to moderate Alzheimer's disease: Results from a randomized, double-blind, placebo-controlled phase III study. Dement. Geriatr. Cogn. Disord. 30, 131-146 (2010
96. Simons, M. et al. Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: A 26-week randomized, placebo-controlled, double-blind trial. Ann. Neurol. 52, 346-350 (2002
97. Sparks, D. L. et al. Atorvastatin for the treatment of mild to moderate Alzheimer disease: Preliminary results. Arch. Neurol. 62, 753-757 (2005
98. Feldman, H. H. et al. Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe. Neurology 74, 956-964 (2010
99. Aisen, P. S. et al. A randomized controlled trial of prednisone in Alzheimer's disease. Alzheimer's Disease Cooperative Study. Neurology 54, 588-593 (2000
100. Wong, W. B., Lin, V. W., Boudreau, D. & Devine, E. B. Statins in the prevention of dementia and Alzheimer's disease: A meta-Analysis of observational studies and an assessment of confounding. Pharmacoepidemiol. Drug Safety 22, 345-358 (2013
101. Stewart, W. F., Kawas, C., Corrada, M. & Metter, E. J. Risk of Alzheimer's disease and duration of NSAID use. Neurology 48, 626-632 (1997
102. McGeer, P. L., Schulzer, M. & McGeer, E. G. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: A review of 17 epidemiologic studies. Neurology 47, 425-432 (1996
103. Vlad, S. C., Miller, D. R., Kowall, N. W. & Felson, D. T. Protective effects of NSAIDs on the development of Alzheimer disease. Neurology 70, 1672-1677 (2008
104. Chou, R., Kane, M., Ghimire, S. & Gautam, S. Tumour necrosis factor inhibition reduces the incidence of Alzheimer's disease in rheumatoid arthritis patients. Presented at American College of Rheumatology (2010
105. Grande, G. et al. Physical activity reduces the risk of dementia in mild cognitive impairment subjects: A cohort study. J. Alzheimers Dis. http://dx.doi.org/10.3233/JAD-131808
106. Pedersen, B. K. Muscle as a secretory organ. Compr. Physiol. 3, 1337-1362 (2013
107. Browne, T. C. et al. IFN-? production by amyloid β-specific Th1 cells promotes microglial activation and increases plaque burden in a mouse model of Alzheimer's disease. J. Immunol. 190, 2241-2251 (2013
108. Ginhoux, F. et al. Fate mapping analysis reveals that adult microglia derive from primitive macrophages. Science 330, 841-845 (2010
109. Lawson, L. J., Perry, V. H. & Gordon, S. Turnover of resident microglia in the normal adult mouse brain. Neuroscience 48, 405-415 (1992
110. Mildner, A. et al. Distinct and non-redundant roles of microglia and myeloid subsets in mouse models of Alzheimer's disease. J. Neurosci. 31, 11159-11171 (2011
111. Hart, A. D., Wyttenbach, A., Perry, V. H. & Teeling, J. L. Age related changes in microglial phenotype vary between CNS regions: Grey versus white matter differences. Brain Behav. Immun. 26, 754-765 (2012
112. Lawson, L. J., Perry, V. H., Dri, P. & Gordon, S. Heterogeneity in the distribution and morphology of microglia in the normal adult mouse brain. Neuroscience 39, 151-170 (1990
113. Mittelbronn, M., Dietz, K., Schluesener, H. J. & Meyermann, R. Local distribution of microglia in the normal adult human central nervous system differs by up to one order of magnitude. Acta Neuropathol. 101, 249-255 (2001
114. Mouton, P. R. et al. Age and gender effects on microglia and astrocyte numbers in brains of mice. Brain Res. 956, 30-35 (2002
115. Sheng, J. G., Mrak, R. E. & Griffin, W. S. Enlarged and phagocytic, but not primed, interleukin 1a immunoreactive microglia increase with age in normal human brain. Acta Neuropath. 95, 229-234 (1998
116. Hoek, R. M. et al. Down-regulation of the macrophage lineage through interaction with OX2 (CD200). Science 290, 1768-1771 (2000
117. Cardona, A. E. et al. Control of microglial neurotoxicity by the fractalkine receptor. Nat. Neurosci. 9, 917-924 (2006
118. Gitik, M., Liraz-Zaltsman, S., Oldenberg, P. A., Reichert, F. & Rotshenker, S. Myelin Downregulates myelin phagocytosis by microglia and macrophages through interactions between CD47 and SIRPa (signal regulatory protein a) on phagocytes. J. Neuroinflammation 8, 24 (2011
119. Wang, Y. & Neumann, H. Alleviation of neurotoxicity by microglial human Siglec 11. J. Neurosci. 30, 3482-3488 (2010.